Key result
Aliskiren, the first oral direct renin inhibitor, is discussed as a new class of antihypertensive drug for the pharmacotherapy of hypertension based on new evidence.
This review discusses the role of aliskiren, a direct renin inhibitor, in the pharmacotherapy of hypertension.
Aliskiren may expand antihypertensive options via direct renin inhibition; leaves open its comparative efficacy and safety in practice.
The RAAS is an important pharmacologic target as the system is involved in cardiovascular (CV) and renovascular disease. Ang II is the key component of RAAS. The intervention to the RAAS can be achieved in different stages. While angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are two big groups that target the RAAS, aliskiren a direct renin inhibitor that became clinically feasible in 2007 with the launch of aliskiren. In this review, we will discuss direct renin inhibition as a new concept for pharmacotherapy of hypertension and aliskiren, the first oral direct renin inhibitor, as a new class of antihypertensive drug based on new evidence.
No takes yet. Share an insight, caveat, or question.
Fehmi Mercanoğlu (2015) conducted a review in hypertension. aliskiren was evaluated. Aliskiren, the first oral direct renin inhibitor, is discussed as a new class of antihypertensive drug for the pharmacotherapy of hypertension based on new evidence.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: